TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35779110
Drug: Behavioral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapy (BT) + pelvic floor muscle training (PFMT) + anticholinergic + beta3‐agonist
Study: 35779110
Drug: Behavioral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapy (BT) + anticholinergic + beta3‐agonist
Study: 32166544
Drug: Systemic sedoanalgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic sedoanalgesia (intravenous remifentanil/fentanyl ± intravenous midazolam ± intravenous acetaminophen/nonsteroidal anti‐inflammatory drugs) + subcutaneous anesthesia (lidocaine)
Study: 32166544
Drug: Mild systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild systemic sedoanalgesia (oral solution morphine sulfate + intravenous midazolam + intravenous acetaminophen) + both subcutaneous and subcapsular anesthesia (mepivacaine + bupivacaine)
Study: 33802381
Drug: Resveratrol (lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol (lower dose)
Study: 33802381
Drug: Resveratrol (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol (higher dose)
Study: 33802381
Drug: Luteolin (lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteolin (lower dose)
Study: 33802381
Drug: Luteolin (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteolin (higher dose)
Study: 33802381
Drug: Fisetin (lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fisetin (lower dose)
Study: 33802381
Drug: Fisetin (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fisetin (higher dose)
Study: 32470438
Drug: Deferiprone (75-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferiprone (75-100 mg/kg per day)
Study: 32470438
Drug: Deferasirox (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferasirox (20-40 mg/kg per day)
Study: 34313812
Drug: Tofacitinib (TOF)
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tofacitinib (TOF) 5 mg orally twice a day
Study: 33055139
Drug: Control (user-determined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (user-determined insulin dosing)
Study: 34077237
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with modified oxaliplatin, leucovorin, and fluorouracil (FOLFOX)
Study: 34077237
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with carboplatin‐paclitaxel (CP)
Study: 33185339
Drug: Targeted antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted antibiotic therapy
Study: 33185339
Drug: Local peloid
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local peloid therapy
Study: 34611700
Drug: Video-assisted anal
Normalized name: Mephitis mephitis anal gland fluid preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video-assisted anal fistula treatment (VAAFT)
Study: 32546278
Drug: Celecoxib (COX2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (COX2 selective inhibitor)
Study: 33578615
Drug: Sham tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham tDCS combined with constraint-induced movement therapy (CIMT)
Study: 34863994
Drug: Quercetin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin (1000 mg daily) + antiviral drugs (remdesivir or favipiravir)
Study: 34863994
Drug: Antiviral drugs
Normalized name: antiviral drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral drugs (remdesivir or favipiravir)
Study: 35909493
Drug: Radial extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial extracorporeal shock wave therapy (rESWT) combined with conventional rehabilitation therapy (CRT)
Study: 35909493
Drug: Conventional rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional rehabilitation therapy (CRT) alone
Study: 35320282
Drug: Cell block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cell block preparation
Study: 35320282
Drug: Combined conventional
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined conventional cytology and cell block preparation
Study: 34599663
Drug: Psychological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological treatment (specifics not provided)
Study: 35840916
Drug: MG plus
Normalized name: MG Plus Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: MG plus A-MRI
Study: 35840916
Drug: MG alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: MG alone
Study: 35384254
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy CD34 antibody‐covered sirolimus‐eluting Combo stent (DTS)
Study: 32409485
Drug: Cenobamate 200
Normalized name: cenobamate 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenobamate 200 mg/d
Study: 34329984
Drug: HS+BT group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: HS+BT group (1,000 mg/kg betaine)
Study: 35373026
Drug: Ziltivekimab 15
Normalized name: Ziltivekimab
DrugBank: Ziltivekimab (DB18836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziltivekimab 15 mg subcutaneous injection
Study: 35373026
Drug: Ziltivekimab 50
Normalized name: Ziltivekimab
DrugBank: Ziltivekimab (DB18836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziltivekimab 50 mg subcutaneous injection
Study: 35373026
Drug: Ziltivekimab 5
Normalized name: Ziltivekimab
DrugBank: Ziltivekimab (DB18836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziltivekimab 5 mg subcutaneous injection
Study: 32532230
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel plus ramucirumab (wPTX + RAM)
Study: 32532230
Drug: Weekly nab-paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly nab-paclitaxel plus ramucirumab (w-nab-PTX + RAM)
Study: 35757181
Drug: Antioxidant supplement
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplement (NingXia RedⓇ), 60 ml daily for 60 days
Study: 32727335
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acids and nano-curcumin combination
Study: 38429253
Drug: Edoxaban (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban (60 mg once daily)
Study: 33169203
Drug: Oxycodone +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone + Alcohol
Study: 35667085
Drug: 1,300mg TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,300mg TXA orally or 1,000mg TXA intravenously thrice daily for maximum 30 days
Study: 34226418
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg atropine and 2 mg neostigmine
Study: 32816002
Drug: Anti-VEGF treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-VEGF treatment, with varying fluctuations in retinal thickness (measured by FCPT SD).
Study: 35148329
Drug: COTiD-UK (Community
Approvals — FDA: no, EMA: no, PMDA: no
Description: COTiD-UK (Community Occupational Therapy in Dementia-UK version)
Study: 35288021
Drug: HRT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT plus letrozole (2.5 mg oral letrozole twice daily for 5 days, with continuation of daily oestradiol)
Study: 35288021
Drug: HRT only
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT only (daily intramuscular progesterone plus daily oestradiol)
Study: 32460396
Drug: Photobiomodulation (PBM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation (PBM) with a dose of 12 J/cm2 during 10 sessions
Study: 32121236
Drug: Omega-3 long
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 long chain polyunsaturated fatty acids (OM, 722 mg/day docosahexaenoic acid)
Study: 34389930
Drug: Patch pump
Normalized name: subcut bolus insulin patch pump,200 unit,disposabl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch pump
Study: 33706870
Drug: Standard systolic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard systolic blood pressure treatment (<140 mm Hg)
Study: 34289428
Drug: Chai Hu
Normalized name: Hu-PHEC Liver
DrugBank: Hu-PHEC Liver (DB18347)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chai Hu oral liquid high dosage
Study: 34289428
Drug: Chai Hu
Normalized name: Hu-PHEC Liver
DrugBank: Hu-PHEC Liver (DB18347)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chai Hu oral liquid middle dosage
Study: 34289428
Drug: Chai Hu
Normalized name: Hu-PHEC Liver
DrugBank: Hu-PHEC Liver (DB18347)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chai Hu oral liquid low dosage
Study: 32398326
Drug: Cardiopulmonary irradiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cardiopulmonary irradiation (specific doses not detailed)
Study: 35647186
Drug: Nicorandil tablets
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil tablets
Study: 34044869
Drug: Sequential implementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential implementation strategy (first centered on nurses, then involving physicians)
Study: 34044869
Drug: Prescription of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription of lifestyle change
Study: 35297768
Drug: Mobile health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile health intervention delivered via an existing service communication app for 10 weeks, including weekly push notifications and resources.
Study: 35466050
Drug: Diltiazem (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (up to 360 mg/d)
Study: 35063267
Drug: telmisartan 40
Normalized name: telmisartan 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: telmisartan 40 mg/day + amlodipine 5 mg/day
Study: 35063267
Drug: telmisartan 40
Normalized name: telmisartan 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: telmisartan 40 mg/day + cilnidipine 10 mg/day
Study: 35394159
Drug: Dexmedetomidine (alpha2-agonist)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (alpha2-agonist)
Study: 35394159
Drug: Yohimbine (alpha2-antagonist)
Normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (alpha2-antagonist)
Study: 33804123
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment (Control)
Study: 33118429
Drug: Spirulina (5.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirulina (5.7 g/d)
Study: 33153313
Drug: Remote symptom
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote symptom monitoring intervention, delivered during daily automated coaching
Study: 35025558
Drug: COPE (Concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: COPE (Concurrent Treatment of PTSD and SUD Using Prolonged Exposure)
Study: 35025558
Drug: Relapse Prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relapse Prevention (RP) therapy for SUD
Study: 37488811
Drug: Apremilast (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apremilast (30 mg twice daily)
Study: 33712987
Drug: Methotrexate (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (0.4 mg/kg/week orally)
Study: 34802925
Drug: Intranasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal administration of dexmedetomidine (0.1 mg kg–1) with midazolam (2 mg kg–1)
Study: 34802925
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of dexmedetomidine (0.1 mg kg–1) with midazolam (2 mg kg–1)
Study: 34802925
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (IN and IM)
Study: 33260183
Drug: Oxycodone combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone combined with propofol (group OP)
Study: 34264835
Drug: Antidepressant Treatment
Normalized name: Antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant Treatment (AT) group
Study: 32331886
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (FM and BM)
Study: 35867199
Drug: Imeglimin (250–8000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imeglimin (250–8000 mg single dose; 250–2000 mg twice daily multiple doses)
Study: 36193713
Drug: Liraglutide 3
Normalized name: liraglutide 3.6 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 3 mg administered subcutaneously daily
Study: 36193713
Drug: Liraglutide 3
Normalized name: liraglutide 3.6 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 3 mg
Study: 32302682
Drug: Postoperative tangential
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative tangential whole breast radiation therapy (RT)
Study: 32302682
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment (Control group)
Study: 32784412
Drug: High-gamma-polyglutamic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-gamma-polyglutamic acid (HPGA) natto (439.6 mg of γ-PGA)
Study: 32784412
Drug: Low-gamma-polyglutamic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-gamma-polyglutamic acid (LPGA) natto (57.6 mg of γ-PGA)
Study: 32293798
Drug: Temsirolimus 115
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Temsirolimus 115 mg weekly and perifosine 100 mg daily (following 600 mg load)
Study: 32293798
Drug: Temsirolimus 50
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Temsirolimus 50 mg (dose level 3)
Study: 32293798
Drug: Temsirolimus 170
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Temsirolimus 170 mg (dose level 7)
Study: 32293798
Drug: Temsirolimus 170
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Temsirolimus 170 mg (dose level 6)
Study: 32293798
Drug: Temsirolimus (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temsirolimus (various doses)
Study: 36121655
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment (control)
Study: 32268867
Drug: Insulin U‐500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin U‐500
Study: 32147078
Drug: 600 IU
Normalized name: Vitamin E 4600 IU/5 ML Oral Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 IU alpha-tocopherol soft gels (200 IU three times daily)
Study: 32147078
Drug: Placebo soft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo soft gels
Study: 33768237
Drug: Secnidazole 2
Normalized name: secnidazole 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secnidazole 2 g single oral dose
Study: 35493455
Drug: mepolizumab 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: mepolizumab 300 mg subcutaneously every 4 weeks for 32 weeks
Study: 36113708
Drug: Craniosacral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Craniosacral therapy (CST) sessions (1-3 sessions until symptoms resolved)
Study: 33831317
Drug: CHO-replace (treadmill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO-replace (treadmill exercise followed by a carbohydrate replacement drink of 200 or 150 g maltodextrin)
Study: 36122810
Drug: Ingesting 75-g
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ingesting 75-g glucose
Study: 35556054
Drug: BH4 (Sapropterin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BH4 (Sapropterin, 10 mg/kg)
Study: 32342496
Drug: Nabiximols (oromucosal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabiximols (oromucosal cannabinoid medicine), 12 sprays/day max based on clinical response/tolerability for 12 weeks
Study: 35606184
Drug: Perioperative nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative nutritional supplements
Study: 36286574
Drug: Customized Photobiomodulation
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Customized Photobiomodulation (PBMT) applied using 850 nm with continuous wave, total of 526-1402 J each session, twice a week for 5 weeks
Study: 33237990
Drug: Mindfulness-exercise group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-exercise group (8-week mindfulness intervention + 18 weeks exercise therapy, 3 sessions/week)
Study: 33237990
Drug: Exercise-only group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise-only group (18 weeks exercise therapy, 3 sessions/week)
Study: 33774458
Drug: 0.15−0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15−0.2 mg/kg nalbuphine
Study: 33774458
Drug: 0.75–1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75–1.0 mg/kg tramadol
Study: 34241688
Drug: Combination method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination method cohort using contrast-enhanced ultrasonography (CEUS) and blue dye (BD) together
Study: 34241688
Drug: Combination method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination method cohort
Study: 34444711
Drug: Berberine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berberine (500 mg orally, twice a day)
Study: 32316918
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of audio and visual distraction
Study: 33827105
Drug: Univariate analyses
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Univariate analyses of 9 depression treatment metrics
Study: 34182951
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (small tidal volume 8 mL/kg + PEEP 5 cmH2O)
Study: 34182951
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (small tidal volume 8 mL/kg + PEEP 5 cmH2O + recruitment maneuvers)
Study: 32323940
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy without cortexin (Control)
Study: 34700679
Drug: Curative intent
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Curative intent radiation therapy
Study: 34700679
Drug: Palliative intent
Normalized name: Various pain palliation radiopharmaceuticals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palliative intent radiation therapy
Study: 34700679
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment volume
Study: 34700679
Drug: Palliative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palliative treatment intent
Study: 36160134
Drug: SoC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SoC plus nitazoxanide (1,000 mg b.i.d.) and atazanavir/ritonavir (300/100 mg od)
Study: 32326954
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive therapy for PTSD (iCT-PTSD)
Study: 32326954
Drug: Internet-delivered stress
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered stress management therapy (iStress-PTSD)
Study: 32115477
Drug: Nalmefene 10
Normalized name: nalmefene 100 MCG in 1 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalmefene 10 mg
Study: 37280688
Drug: Lamotrigine (LTG)
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine (LTG) 300 mg
Study: 34872895
Drug: 180 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 mg of Ellagic Acid (EA) per day for 2 months
Study: 34981592
Drug: Patient Centeredness
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient Centeredness Index (PCI) survey administered to patients with chronic conditions
Study: 33704620
Drug: Doxorubicin 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 40 mg/m2 and lurbinectedin 2.0 mg/m2 on Day 1 q3wk
Study: 33704620
Drug: Doxorubicin 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 40 mg/m2 and lurbinectedin 2.0 mg/m2 on Day 1 q3wk in sensitive disease
Study: 33704620
Drug: Doxorubicin 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 40 mg/m2 and lurbinectedin 2.0 mg/m2 on Day 1 q3wk in resistant disease
Study: 32852553
Drug: Education and
Normalized name: zinc pyrithione Medicated Shampoo [Free and Clear]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education and personalized text message reminders daily to prompt directly supervised therapy (intervention group)
Study: 33528110
Drug: Partially guided
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partially guided template (test group 1, 36 implants)
Study: 33528110
Drug: Fully guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fully guided template (test group 2, 33 implants)
Study: 33528110
Drug: Routine implant‐supported
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine implant‐supported restoration treatment (control group, 30 implants)
Study: 32862007
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (40 i.u.)
Study: 33106606
Drug: PEG‐ELS 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐ELS 40 (40 ml/kg)
Study: 33106606
Drug: PEG‐ELS 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐ELS 60 (60 ml/kg)
Study: 35382059
Drug: IV dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV dexmedetomidine 1 µg/kg over 10 min
Study: 35266219
Drug: FGE dark
Normalized name: dark leaved mugwort pollen extract
DrugBank: Artemisia ludoviciana pollen (DB10762)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FGE dark chocolate (5 g/day containing 650 mg of FGE powder)
Study: 32016118
Drug: Intravitreal Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal Bevacizumab (IVB) plus topical dorzolamide 2% twice daily
Study: 32016118
Drug: Intravitreal Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal Bevacizumab (IVB) alone plus topical artificial tear twice daily